Morgan Stanley assumed coverage on shares of Structure Therapeutics (NASDAQ:GPCR – Free Report) in a research note published on Monday morning, MarketBeat Ratings reports. The firm issued an overweight rating and a $118.00 price objective on the stock.
Several other brokerages have also issued reports on GPCR. Cantor Fitzgerald reaffirmed an overweight rating and set a $65.00 target price on shares of Structure Therapeutics in a research report on Monday, September 16th. JMP Securities decreased their price objective on Structure Therapeutics from $91.00 to $86.00 and set a market outperform rating for the company in a report on Friday, August 9th. Finally, BMO Capital Markets lifted their price objective on Structure Therapeutics from $83.00 to $100.00 and gave the stock an outperform rating in a report on Friday, June 7th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of Buy and a consensus target price of $88.33.
Get Our Latest Analysis on Structure Therapeutics
Structure Therapeutics Trading Down 1.0 %
Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. On average, sell-side analysts forecast that Structure Therapeutics will post -0.86 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the stock. Teachers Retirement System of The State of Kentucky boosted its stake in Structure Therapeutics by 28.5% in the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 17,651 shares of the company’s stock worth $693,000 after purchasing an additional 3,918 shares during the period. Perceptive Advisors LLC bought a new position in Structure Therapeutics in the 2nd quarter worth about $1,369,000. Quarry LP bought a new position in Structure Therapeutics in the 2nd quarter worth about $79,000. Driehaus Capital Management LLC boosted its position in shares of Structure Therapeutics by 3.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company’s stock valued at $101,204,000 after acquiring an additional 86,833 shares during the last quarter. Finally, Blue Owl Capital Holdings LP bought a new stake in shares of Structure Therapeutics during the 2nd quarter valued at about $2,160,000. Institutional investors own 91.78% of the company’s stock.
Structure Therapeutics Company Profile
Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
Featured Articles
- Five stocks we like better than Structure Therapeutics
- The 3 Best Retail Stocks to Shop for in August
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- How to Invest in Blue Chip Stocks
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- 3 REITs to Buy and Hold for the Long Term
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.